Meyhöfer, Svenja; Eckert, Alexander J; Hummel, Michael; Laimer, Markus; Roden, Michael; Kress, Stephan; Seufert, Jochen; Meyhöfer, Sebastian M; Holl, Reinhard W (2022). Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database. Diabetes, obesity & metabolism, 24(4), pp. 727-732. Wiley 10.1111/dom.14616
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Diabetes_Obesity_Metabolism_-_2021_-_Meyh_fer_-_Elevated_liver_enzymes_and_comorbidities_in_type_2_diabetes_A_multicentre.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (836kB) |
AIM
To assess the prevalence of elevated liver enzymes and associated diabetes-related comorbidities in type 2 diabetes (T2D).
SUBJECTS AND METHODS
Between 2010 and 2019, 281 245 patients with T2D (aged 18-75 years) from 501 Diabetes Prospective Follow-up (DPV) centres were evaluated, resulting in analysis of 51 645 patients with complete data on demographics and liver enzymes.
RESULTS
Elevated liver enzymes were found in 40.2% of all patients. However, only 8.6% of these patients had International Classification of Diseases-10 codes for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Adjusted for age, sex, diabetes duration, body mass index and glycated haemoglobin, a higher prevalence of arterial hypertension (P < 0.0001), dyslipidaemia (P < 0.0001), peripheral artery disease (P = 0.0029), myocardial infarction (P = 0.0003), coronary artery disease (P = 0.0001), microalbuminuria (P < 0.0001) and chronic kidney disease (P < 0.0001) was seen in patients with elevated versus normal liver enzymes. The prevalence of elevated liver enzymes was lowest in patients receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors or a combination of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists.
CONCLUSION
Elevated liver enzymes are common in patients with T2D and clearly correlate with a higher prevalence of clinically relevant comorbidities. Assessing liver enzymes should be standard clinical routine in T2D due to a possible predictive role for comorbidities and complications.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition |
UniBE Contributor: |
Laimer, Markus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1463-1326 |
Publisher: |
Wiley |
Language: |
English |
Submitter: |
Markus Laimer |
Date Deposited: |
11 Mar 2022 13:26 |
Last Modified: |
19 May 2023 07:14 |
Publisher DOI: |
10.1111/dom.14616 |
PubMed ID: |
34882949 |
Uncontrolled Keywords: |
GLP-1 receptor agonists NAFLD SGLT2 inhibitors liver enzymes metabolic syndrome type 2 diabetes |
BORIS DOI: |
10.48350/167186 |
URI: |
https://boris.unibe.ch/id/eprint/167186 |
Actions (login required)
 |
Edit item |